vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and OLAPLEX HOLDINGS, INC. (OLPX). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $105.1M, roughly 1.7× OLAPLEX HOLDINGS, INC.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -12.5%, a 25.8% gap on every dollar of revenue. On growth, OLAPLEX HOLDINGS, INC. posted the faster year-over-year revenue change (4.3% vs -1.8%). OLAPLEX HOLDINGS, INC. produced more free cash flow last quarter ($32.6M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 3.1%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
AMPH vs OLPX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $105.1M |
| Net Profit | $24.4M | $-13.1M |
| Gross Margin | 46.8% | 68.0% |
| Operating Margin | 19.4% | -4.3% |
| Net Margin | 13.3% | -12.5% |
| Revenue YoY | -1.8% | 4.3% |
| Net Profit YoY | -35.7% | -48.9% |
| EPS (diluted) | $0.51 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $105.1M | ||
| Q3 25 | $191.8M | $114.6M | ||
| Q2 25 | $174.4M | $106.3M | ||
| Q1 25 | $170.5M | $97.0M | ||
| Q4 24 | $186.5M | $100.7M | ||
| Q3 24 | $191.2M | $119.1M | ||
| Q2 24 | $182.4M | $103.9M | ||
| Q1 24 | $171.8M | $98.9M |
| Q4 25 | $24.4M | $-13.1M | ||
| Q3 25 | $17.4M | $11.1M | ||
| Q2 25 | $31.0M | $-7.7M | ||
| Q1 25 | $25.3M | $465.0K | ||
| Q4 24 | $38.0M | $-8.8M | ||
| Q3 24 | $40.4M | $14.8M | ||
| Q2 24 | $37.9M | $5.8M | ||
| Q1 24 | $43.2M | $7.7M |
| Q4 25 | 46.8% | 68.0% | ||
| Q3 25 | 51.4% | 69.1% | ||
| Q2 25 | 49.6% | 71.2% | ||
| Q1 25 | 50.0% | 69.5% | ||
| Q4 24 | 46.5% | 66.3% | ||
| Q3 24 | 53.3% | 68.6% | ||
| Q2 24 | 52.2% | 69.7% | ||
| Q1 24 | 52.4% | 72.1% |
| Q4 25 | 19.4% | -4.3% | ||
| Q3 25 | 13.2% | 3.7% | ||
| Q2 25 | 24.2% | -1.1% | ||
| Q1 25 | 21.9% | 8.7% | ||
| Q4 24 | 24.2% | 3.0% | ||
| Q3 24 | 29.8% | 23.5% | ||
| Q2 24 | 30.3% | 15.7% | ||
| Q1 24 | 27.9% | 19.8% |
| Q4 25 | 13.3% | -12.5% | ||
| Q3 25 | 9.0% | 9.7% | ||
| Q2 25 | 17.8% | -7.3% | ||
| Q1 25 | 14.8% | 0.5% | ||
| Q4 24 | 20.4% | -8.7% | ||
| Q3 24 | 21.1% | 12.4% | ||
| Q2 24 | 20.8% | 5.6% | ||
| Q1 24 | 25.1% | 7.8% |
| Q4 25 | $0.51 | $-0.02 | ||
| Q3 25 | $0.37 | $0.02 | ||
| Q2 25 | $0.64 | $-0.01 | ||
| Q1 25 | $0.51 | $0.00 | ||
| Q4 24 | $0.74 | $-0.01 | ||
| Q3 24 | $0.78 | $0.02 | ||
| Q2 24 | $0.73 | $0.01 | ||
| Q1 24 | $0.81 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $318.7M |
| Total DebtLower is stronger | $608.7M | $352.3M |
| Stockholders' EquityBook value | $788.8M | $879.4M |
| Total Assets | $1.6B | $1.5B |
| Debt / EquityLower = less leverage | 0.77× | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $318.7M | ||
| Q3 25 | $276.2M | $286.4M | ||
| Q2 25 | $231.8M | $289.3M | ||
| Q1 25 | $236.9M | $580.9M | ||
| Q4 24 | $221.6M | $586.0M | ||
| Q3 24 | $250.5M | $538.8M | ||
| Q2 24 | $217.8M | $507.9M | ||
| Q1 24 | $289.6M | $507.5M |
| Q4 25 | $608.7M | $352.3M | ||
| Q3 25 | $608.6M | $352.1M | ||
| Q2 25 | $607.7M | $351.9M | ||
| Q1 25 | $603.9M | $649.1M | ||
| Q4 24 | $601.6M | $650.5M | ||
| Q3 24 | $596.4M | $651.8M | ||
| Q2 24 | $586.9M | $653.1M | ||
| Q1 24 | $594.0M | $654.4M |
| Q4 25 | $788.8M | $879.4M | ||
| Q3 25 | $776.7M | $888.7M | ||
| Q2 25 | $757.5M | $874.2M | ||
| Q1 25 | $751.3M | $878.3M | ||
| Q4 24 | $732.3M | $874.4M | ||
| Q3 24 | $727.7M | $879.7M | ||
| Q2 24 | $713.3M | $863.3M | ||
| Q1 24 | $672.4M | $855.7M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.8B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.5B | $1.8B | ||
| Q1 24 | $1.6B | $1.8B |
| Q4 25 | 0.77× | 0.40× | ||
| Q3 25 | 0.78× | 0.40× | ||
| Q2 25 | 0.80× | 0.40× | ||
| Q1 25 | 0.80× | 0.74× | ||
| Q4 24 | 0.82× | 0.74× | ||
| Q3 24 | 0.82× | 0.74× | ||
| Q2 24 | 0.82× | 0.76× | ||
| Q1 24 | 0.88× | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $32.7M |
| Free Cash FlowOCF − Capex | $24.6M | $32.6M |
| FCF MarginFCF / Revenue | 13.4% | 31.0% |
| Capex IntensityCapex / Revenue | 4.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $58.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $32.7M | ||
| Q3 25 | $52.6M | $8.0M | ||
| Q2 25 | $35.6M | $20.9M | ||
| Q1 25 | $35.1M | $-2.9M | ||
| Q4 24 | $29.0M | $49.7M | ||
| Q3 24 | $60.0M | $33.5M | ||
| Q2 24 | $69.1M | $16.2M | ||
| Q1 24 | $55.3M | $43.7M |
| Q4 25 | $24.6M | $32.6M | ||
| Q3 25 | $47.2M | $7.9M | ||
| Q2 25 | $25.0M | $20.8M | ||
| Q1 25 | $24.4M | $-3.0M | ||
| Q4 24 | $16.6M | $49.2M | ||
| Q3 24 | $46.2M | $33.3M | ||
| Q2 24 | $63.1M | $16.1M | ||
| Q1 24 | $46.5M | $43.3M |
| Q4 25 | 13.4% | 31.0% | ||
| Q3 25 | 24.6% | 6.9% | ||
| Q2 25 | 14.3% | 19.6% | ||
| Q1 25 | 14.3% | -3.1% | ||
| Q4 24 | 8.9% | 48.9% | ||
| Q3 24 | 24.1% | 28.0% | ||
| Q2 24 | 34.6% | 15.5% | ||
| Q1 24 | 27.1% | 43.7% |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 6.1% | 0.1% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.4% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 0.72× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | -6.27× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 2.26× | ||
| Q2 24 | 1.82× | 2.81× | ||
| Q1 24 | 1.28× | 5.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
